alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
38618.

#### HOLCOMB v. JOHNSTON *et al.*

Felton, Chief Judge.

Where a citation seeking a judgment for criminal contempt is filed as a branch of an equity case in which the judgment enjoined the defendant from committing *117the acts which form the basis for the contempt citation, the contempt case comes within the jurisdiction of the court having jurisdiction of the equity case. This situation exists, where, as in the instant case, the petition for citation for contempt is instituted by the plaintiffs in the equity case and is entitled in the equity case. The same jurisdictional consequence obtains in a case arising out of a petition by a defendant adjudged in contempt for a modification of the contempt judgment against the plaintiffs in the equity case, especially when, as here, the petition for modification is entitled in the equity case. *Alred v. Celanese Corp. of America,*205 Ga. 371, 391 (54 S. E. 2d 240); *Atlanta Printing Specialties &c. Union No. 527, AFL-CIO v. Zell,*215 Ga. 732 (113 S. E. 2d 401); *Bennett v. Bagwell & Stewart, Inc.,*216 Ga. 290 (116 S. E. 2d 288). The case is accordingly

Decided February 1, 1961.

*Thomas C. Burton, Herbert B. Kimzey, Kimzey & Kimzey,*for plaintiff in error.

*Paul M. Conaway, McClure, Ramsay & Struble, George B. Ramsay, Jr.,*contra.

*Transferred to the Supreme Court.*

*Nichols and Bell, JJ., concur.*
§ 335.10 Antidiarrheal active ingredients. The active ingredient of the product consists of any one of the following when used within the dosage limits established for each ingredient in § 335.50(d): ( a ) Bismuth subsalicylate.
( b ) Kaolin.
##### 



EXHIBIT 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Front Range Capital Corporation (the
Company) on Form 10-QSB for the period ending June 30, 2003, as filed with
the Securities and Exchange Commission on the date hereof (the Report), I,
Alice M. Bier, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of
2002, that:

(1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.



| | /s/ Alice M. Bier
Alice M. Bier
Chief Financial Officer
| | -------------------------------------------------------

August 13, 2003

A signed original of this written statement required by Section 906 has been
provided to Front Range Capital Corporation and will be retained by Front Range
Capital Corporation and furnished to the Securities and Exchange Commission or
its staff upon request.
§ 522.650 Dihydrostreptomycin sulfate injection. ( a ) *Specifications.* Each milliliter contains dihydrostreptomycin sulfate equivalent to 500 milligrams of dihydrostreptomycin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerance.* See § 556.200 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* Administer 5 milligrams per pound of body weight by deep intramuscular injection every 12 hours, for 3 to 5 days or until the urine is free of leptospira for at least 72 hours as measured by darkfield microscopic examination.
( 2 ) *Indications for use.* Treatment of leptospirosis in dogs and horses due to *Leptospira canicola, L. icterohemorrhagiae,* and *L. pomona;* in cattle due to *L. pomona;* and in swine due to *L. pomona;* and *L. grippotyphosa.*
( 3 ) *Limitations.* Discontinue use 30 days before slaughter for food. Not for use in animals producing milk because use of the drug will contaminate the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37331, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 79 FR 16187, Mar. 25, 2014; 85 FR 18119, Apr. 1, 2020]
§ 606.110 Plateletpheresis, leukapheresis, and plasmapheresis. ( a ) The use of plateletpheresis and leukapheresis procedures to obtain a product for a specific recipient may be at variance with the additional standards for specific products prescribed in this part provided that: ( 1 ) A physician has determined that the recipient must be transfused with the leukocytes or platelets from a specific donor, and
( 2 ) the procedure is performed under the supervision of a responsible physician who is aware of the health status of the donor, and the physician has determined and documented that the donor's health permits plateletpheresis or leukapheresis.
( b ) Plasmapheresis of donors who do not meet the donor requirements of §§ 630.10, 630.15, 640.64 and 640.65 of this chapter for the collection of plasma containing rare antibodies shall be permitted only with the prior approval of the Director, Center for Biologics Evaluation and Research.
[40 FR 53532, Nov. 18, 1975, as amended at 49 FR 23833, June 8, 1984; 55 FR 11013, Mar. 26, 1990; 80 FR 29895, May 22, 2015]
§ 1.95 Application for authorization to relabel and recondition. Application for authorization to relabel or perform other action to bring the article into compliance with the Federal Food, Drug, and Cosmetic Act or to render it other than a food, drug, device, or cosmetic may be filed only by the owner or consignee, and shall: ( a ) Contain detailed proposals for bringing the article into compliance with the act or rendering it other than a food, drug, device, or cosmetic.
( b ) Specify the time and place where such operations will be carried out and the approximate time for their completion.
[42 FR 15553, Mar. 22, 1977, as amended at 85 FR 50781, Aug. 18, 2020]
Editorial Note on Part 173
Editorial Note: Nomenclature changes to part 173 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; and 81 FR 49896, July 29, 2016.

§ 173.385 Sodium methyl sulfate. Sodium methyl sulfate may be present in pectin in accordance with the following conditions. ( a ) It is present as the result of methylation of pectin by sulfuric acid and methyl alcohol and subsequent treatment with sodium bicarbonate.
( b ) It does not exceed 0.1 percent by weight of the pectin.
# Fourth Court of Appeals

San Antonio, Texas

February 27, 2014

N o. 04

- 14

- 00092

- CV

IN THE INTEREST OF A.E., JR., ET AL., CHILDREN,

From the 45th Judicial District Court, Bexar County, Texas

Trial Court No. 2013

- PA

- 00722

Honorable Charles E. Montemayor, Judge Presiding



### O R D E R

The District Clerk's notification of late record is hereby GRANTED. The record is due

February 28, 2014.

_________________________________ Sandee Bryan Marion, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said

court on this 27th day of February, 2014

.

___________________________________ Keith E. Hottle

Clerk of Court
# A~~tAl·DtMOCRAI 1530 Ellis l.ak.e Dr .. P.O . Box -'31, Marys..tle, CA 95901 (916) 741-2345 

# Affidavit of Publication (2015.5 C.C.P.) 

# STATE OF CALIFORNIA,] County of Yuba, ss . 

## Fea t h e r River Air**Qual~ty Mg~**  

## Not . of Pub. Meeting 7/6/98

I am not a party t o. or Int e rest ed In the abov e entitled 

### matter . I am th e principal cler1< of the print er and publisher

of THE APPEAL-DEMOCRAT

. a newspaper of general

drculat1on. printed & published In th e Oty of Marysville.

ColX'lty of 'r\Jba. and which Newspaper

has been adjudged a newspaper of general

circ ulation by the Superior Court o f tha County of 'r\Jba,

State of Callfomla under the date of Nov ember

9.

1951. No. 11481. that the notice of whi ch the annexed



### Is a printed copy (set In type not smaller than

nonpareiO

. has been published In each regula r and

entire Issue of sold newspa pe r and not In an y

supplement ther eof on the foll owing dates. to-wtt : 

## June 3, 1998

I decla r e un der penatty of

**pe~ury**

t hat the forego ing I s true and correct.

E

xec uted at Marysville. California. Th is space Is for the County Clerk's filing stomp. 

# FEA THEA RIVER AQMD PROOF OF PUBUCATION NOTICE OF PUBLIC MEETING The

Feather River Air Quality Management District

(FRAQMDJ will hold a public hearing on Monday, July 6th,

1998at 4 : 00p.m. toconsiderthefollowing:
A . Amendment to Rule 7.9, Air Toxic Hot Spats Fees,

to setthefee fort he 1997/JBfiscal year . 8. Adoption of Rule 3.19, Vehicle and Mobile Equip-

mentCooting Operations.

C. Approval of Indi r ect Source Guidelines, which contain

procedures identifying proJects that may

hove a significant effectonairqualitv

. The public hearing will be held at the FRAQMD office

, 938

14th Street

, Marysville. Copies of the proPOsals ore available
at

th e FRAQMD office on weekdays from 8 om · 12 pm and 1 pm

- 5 pm . Written comments must be submitted to the

FRAQMD office by 5 pm, June 30th and the public may

present testimony otthe hearing.June3

AD#l0320238
Editorial Note on Part 60
Editorial Note: Nomenclature changes to part 60 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 60.40 Request for hearing. ( a ) Any person may request, not later than 60 days after the publication under § 60.34(a) of FDA's due diligence determination, that FDA conduct an informal hearing on the due diligence determination.
( b ) The request for a hearing under this section shall: ( 1 ) Be sent by mail, personal delivery, or any other mode of written communication to the Dockets Management Staff and filed under the relevant product file;
( 2 ) Specify the facts and the action that are the subject of the hearing;
( 3 ) Provide the name and address of the person requesting the hearing; and
( 4 ) Certify that the requesting party has served a true and complete copy of the request upon the petitioner and the applicant by certified or registered mail (return receipt requested) or by personal delivery.
( c ) The request shall state whether the requesting party seeks a hearing within 30 days or 60 days of FDA's receipt of the request.
[53 FR 7305, Mar. 7, 1988, as amended at 67 FR 9585, Mar. 4, 2002]
November 24, 2015

Mr. Jon Rocha

Prescott Realty, Inc.

5360 West Inscription Canyon Drive

Prescott, AZ 863005

Dear Mr. Rocha:

This letter is to inform you that we are unable to process your petition for an exemption. It 

explains why we cannot process your request and what you should do in the next 30 days.

Why We Cannot Process Your Request

We received your July 3, 2015, exemption request filed in Docket No. FAA−2015−3787, but 

we are unable to process your request any further as a result of a discrepancy in your petition. 

The name of the petitioner is inconsistent in your petition. For us to consider the request any 

further, you must clarify the name of the petitioner and resubmit a revised petition to your 

docket. 

What You Should Do

If you want us to process your request any further, you must submit the requested information 

within 30 days. Please note that § 11.63(d) requires you to send your petition for exemption 

at least 120 days before the proposed effective date of the exemption. 

If We Do Not Hear From You

If we do not receive the information, we will close the docket without notifying you further. 

If you have any questions, you may call the 333 Information Line at (202) 267-2999.

Sincerely,

/s/

Brittany Newton

Program Analyst, Airmen and 

 Airspace Rules Division
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

JUDGMENT RENDERED JULY 25, 2023

NO. 03-21-00619-CR

Edward Raynard Lampkin, Appellant

v.

The State of Texs, Appellee

APPEAL FROM COMAL COURT AT LAW NO. 3 OF COMAL COUNTY

BEFORE CHIEF JUSTICE BYRNE, JUSTICES TRIANA AND THEOFANIS

AFFIRMED -- OPINION BY CHIEF JUSTICE BYRNE

This is an appeal from the judgment of conviction entered by the trial court. Having reviewed 

the record and the parties’ arguments, the Court holds that there was no reversible error in the 

trial court’s judgment of conviction. Therefore, the Court affirms the trial court’s judgment of 

conviction. The appellant shall pay all costs relating to this appeal, both in this Court and in the 

court below.
§ 522.536 Detomidine. ( a ) *Specification.* Each milliliter of solution contains 10 milligrams of detomidine hydrochloride.
( b ) *Sponsor.* See Nos. 015914, 052483, and 059399 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* For sedation, analgesia, or sedation and analgesia: 20 or 40 micrograms per kilogram (0.2 or 0.4 milliliter per 100 kilogram or 220 pounds) by body weight, depending on depth and duration required. For sedation, administer by intraveneous (IV) or intramuscular (IM) injection; for analgesia, administer by IV injection; for both sedation and analgesia, administer by IV injection.
( 2 ) *Indication for use.* As a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16186, Mar. 25, 2014, as amended at 86 FR 13184, Mar. 8, 2021; 88 FR 27699, May 3, 2023]
# L_2019250EN.01008201.xml

| 30.9.2019 | EN | Official Journal of the European Union | L 250/82 |
| --- | --- | --- | --- |

30.9.2019

EN

Official Journal of the European Union

L 250/82

---

COUNCIL DECISION (EU) 2019/1611

of 24 September 2019

appointing an alternate member, proposed by the Federal Republic of Germany, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the German Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020.

| (2) | An alternate member's seat on the Committee of the Regions has become vacant following the end of mandate on the basis of which Mr Heinz-Joachim HÖFER (Bürgermeister der Stadt Altenkirchen) was proposed, |
| --- | --- |

(2)

An alternate member's seat on the Committee of the Regions has become vacant following the end of mandate on the basis of which Mr Heinz-Joachim HÖFER (Bürgermeister der Stadt Altenkirchen) was proposed,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as an alternate member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

| — | Mr Heinz-Joachim HÖFER, Mitglied des Stadtrates der Kreisstadt Altenkirchen (Westerwald) (change of mandate). |
| --- | --- |

—

Mr Heinz-Joachim HÖFER, Mitglied des Stadtrates der Kreisstadt Altenkirchen (Westerwald) (change of mandate).

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 24 September 2019.

For the Council

The President

K. KULMUNI

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

---
§ 529.1660 Oxytetracycline. ( a ) *Specifications.* ( 1 ) Each gram of powder contains 366 milligrams (mg) oxytetracycline hydrochloride.
( 2 ) Each gram of powder contains 753 mg oxytetracycline hydrochloride.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for use of products described in paragraph (a) of this section as in paragraph (d) of this section. ( 1 ) Nos. 054771 and 061133 for use of product in paragraph (a)(1) of this section.
( 2 ) Nos. 054771, 061133, and 069254 for use of product described in paragraph (a)(2) of this section.
( c ) *Related tolerances. See* § 556.500 of this chapter.
( d ) *Conditions of use in finfish* — ( 1 ) *Amount.* Immerse fish in a solution containing 200 to 700 mg oxytetracycline hydrochloride (buffered) per liter of water for 2 to 6 hours.
( 2 ) *Indications for use.* For skeletal marking of finfish fry and fingerlings.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[69 FR 6557, Feb. 11, 2004, as amended at 69 FR 61999, Oct. 22, 2004; 70 FR 41140, July 18, 2005; 72 FR 26289, May 9, 2007; 76 FR 17026, Mar. 28, 2011; 79 FR 10973, Feb. 27, 2014; 81 FR 22524, Apr. 18, 2016; 81 FR 94991, Dec. 27, 2016; 84 FR 8974, Mar. 13, 2019]
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsConcept of Operations for Urban Air Mobility Command and Control CommunicationsUrban Air Mobility (UAM) is a burgeoning flight services concept for passenger and cargo airborne applications operating within and around urban environments. Among the services envisioned, most attention is being directed at airborne personal transport to improve transit time and mitigate automobile congestion. In addition, delivery services for more efficient transport of goods and local area information gathering for timely media dissemination and emergency monitoring will also likely be early UAM system applications. Among the infrastructure components in need of development are communications systems that manage these air vehicles. Not only will there be a need to communicate with the pilots in command of the aircraft for traffic management, but the control of the aircraft and monitoring of the aircraft systems will also need to use these communications systems to ensure safe operations.Document ID20190002633Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsGreenfeld, Israel*(NASA Glenn Research Center Cleveland, OH, United States)*Date AcquiredApril 22, 2019Publication DateApril 1, 2019Subject CategoryAircraft Communications And NavigationReport/Patent NumberGRC-E-DAA-TN64458NASA/TM-2019-220159E-19676Funding Number(s)WBS: 357672.04.08.03.05Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Technical ReviewSingle ExpertKeywordsUrban Air Mobility (UAM)Command and Control (C2)Unmanned Aerial Vehicle (UAV)Remote Pilot in Command (RPIC)Available DownloadsNameType20190002633.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
§ 556.185 Diclazuril. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of diclazuril is 25 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for diclazuril are: ( 1 ) *Chickens and turkeys.* ( i ) Liver: 3 ppm.
( ii ) Muscle: 0.5 ppm.
( iii ) Skin/fat: 1 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See § 558.205 of this chapter.
[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]
[No. 14668-5-III.

Division Three.

December 16, 1997.]

#### The State of Washington, *Respondent,*v. Gerald William Morris, *Appellant.*

Appeal from a judgment of the Superior Court for Franklin County, No. 94-1-50223-8, Dennis D. Yule, J., entered January 31, 1995. *Reversed*by unpublished opinion per Brown, J., concurred in by Sweeney, C.J., and Schultheis, J.
### Michigan Supreme Court Lansing, Michigan

Robert P. Young, Jr.,
Chief Justice

Michael F. Cavanag h Marilyn Kell y Stephen J. Markma n Diane M. Hathawa y Mary Beth Kell y Brian K. Zahra,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk March 8, 2011

0228 

# Order

March 8, 2011

142122

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee,

v SC: 142122 COA: 300053 Kent CC: 09-002014-FC DARRYL EDWARD CHANEY, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the October 15, 2010 order of the Court of Appeals is consider ed, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Kideo
Productions, Inc, and is qualified in it's entirety be reference to such
financial statements.
</LEGEND>
<MULTIPLIER>                   1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                        JUL-31-1999
<PERIOD-START>                           AUG-01-1998
<PERIOD-END>                             JUL-31-1999
<CASH>                                            86
<SECURITIES>                                       0
<RECEIVABLES>                                    112
<ALLOWANCES>                                       0
<INVENTORY>                                       49
<CURRENT-ASSETS>                                 379
<PP&E>                                         1,019
<DEPRECIATION>                                  (867)
<TOTAL-ASSETS>                                   877
<CURRENT-LIABILITIES>                          3,230
<BONDS>                                            4
<PREFERRED-MANDATORY>                              0
<PREFERRED>                                        0
<COMMON>                                           0
<OTHER-SE>                                    (2,357)
<TOTAL-LIABILITY-AND-EQUITY>                     877
<SALES>                                        4,842
<TOTAL-REVENUES>                               4,842
<CGS>                                          2,201
<TOTAL-COSTS>                                  3,203
<OTHER-EXPENSES>                                   0
<LOSS-PROVISION>                                   0
<INTEREST-EXPENSE>                             1,014
<INCOME-PRETAX>                               (1,576)
<INCOME-TAX>                                       0
<INCOME-CONTINUING>                           (1,576)
<DISCONTINUED>                                     0
<EXTRAORDINARY>                                    0
<CHANGES>                                          0
<NET-INCOME>                                  (1,576)
<EPS-BASIC>                                   (.42)
<EPS-DILUTED>                                   (.42)



</TABLE>